Trinity Capital, an international alternative asset manager, committed $30 million in growth capital to Iantrek, a medical technology company in the bio-interventional ophthalmic surgery (BIOS) space.
“We believe Iantrek’s innovative technology, strong clinical evidence and early commercialization results position them well to be a leader in surgical ophthalmology,” Rob Lake, senior managing director, life sciences at Trinity Capital, said. “We are pleased to support their team as they enter this next phase of rapid growth.”
This debt facility follows a successful series C raise in 2025, which closed in 2025 and included lead equity investors USVP, Sectoral, aMoon and Visionary Ventures. Trinity’s growth capital will support Iantrek in accelerating commercial expansion of its product portfolio, advancing development and regulatory activities for pipeline products, scaling manufacturing and distribution capabilities, and strengthening market access initiatives to broaden physician and patient adoption.
“This financing is a strategic step to keep pace with growing physician demand for our platform,” Adam Szaronos, CEO of Iantrek, said. “It positions us to accelerate adoption of AlloFlo Uveo, our lead commercial technology and advance the next wave of bio-interventional innovation.”
